| Regorafenib Basic information |
| Product Name: |
Regorafenib |
| Synonyms: |
Regorafenib;BAY 73-4506;4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide;BAY 73-4506(Regorafenib);4-[4-({[4-chioro-3-(trifluoroMethyl)phenyl]carbaMoyl}aMino)-3-fluorophenoxy]-pyridine-2-carboxylic acid MethylaMide;Regorafenib (BAY 73-4506);4-[4-[[[[4-Chloro-3-(trifluoroMethyl)phenyl]aMino]carbonyl]aMino]-3-fluorophenoxy]-N-Methyl-2-pyridinecarboxaMide;4-[4-[N'-(4-Chloro-3-trifluoroMethylphenyl)ureido]-3- fluorophenoxy]pyridine-2-carboxylic Acid MethylaMide |
| CAS: |
755037-03-7 |
| MF: |
C21H15ClF4N4O3 |
| MW: |
482.8154128 |
| EINECS: |
1308068-626-2 |
| Product Categories: |
Amines;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Anti-cancer&immunity;Inhibitors |
| Mol File: |
755037-03-7.mol |
 |
| |
| Regorafenib Chemical Properties |
| Melting point |
206.0 to 210.0 °C |
| |
| Regorafenib Usage And Synthesis |
| Uses |
It inhibits PDGFR tyrosine kinase with IC50=83nM. It is useful for the treatment of inflammation and as an anti-proliferative agent. |
| Uses |
BAY 73-4506 (Regorafenib) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. |
| Uses |
Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively |
| Definition |
ChEBI: A pyridinecarboxamide obtained by condensation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]pyridine-2-carboxylic acid with methylamine. Used for for the treatment of metastatic colorectal cancer in patients who have previ usly received chemotherapy, anti-EGFR or anti-VEGF therapy. |
|
|
China
